

# Frontiers in Anti-Cancer Drug Discovery

**Editors:**

Atta-ur-Rahman, *FRS*

M. Iqbal Choudhary

**Bentham Books**

# **Frontiers in Anti-Cancer Drug Discovery**

*(Volume 11)*

**Edited by**

**Atta-ur-Rahman, *FRS***

*Honorary Life Fellow,  
Kings College,  
University of Cambridge,  
Cambridge,  
UK*

**&**

**M. Iqbal Choudhary**

*H.E.J. Research Institute of Chemistry,  
International Center for Chemical and Biological Sciences,  
University of Karachi,  
Karachi,  
Pakistan*

## **Frontiers in Anti-Cancer Drug Discovery**

*Volume # 11*

Editors: Atta-ur-Rahman and M. Iqbal Choudhary

ISSN (Online): 1879-6656

ISSN (Print): 2451-8395

ISBN (Online): 978-981-14-2213-3

ISBN (Print): 978-981-14-2212-6

ISBN (Paperback): 978-981-14-7009-7

©2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	ii
<b>CHAPTER 1 PI3K/AKT/MTOR PATHWAY IN ACUTE LYMPHOBLASTIC LEUKEMIA TARGETED THERAPIES</b> .....	1
<i>Carolina Simioni, Giorgio Zauli, Daniela Milani and Luca M. Neri</i>	
<b>INTRODUCTION</b> .....	1
Acute Lymphoblastic Leukemia .....	3
PI3K/Akt/mTOR Signaling .....	5
Aberrant PI3K/Akt/mTOR Expression in ALL .....	7
<i>PI3K Inhibition in ALL</i> .....	8
<i>Akt Inhibition</i> .....	10
<i>Classes of mTOR Inhibitors: Roles of Rapamycin, Rapalogs, Dual PI3K/mTOR Inhibitors and TORKIs</i> .....	12
Clinical Trials .....	19
<i>PI3K Inhibition</i> .....	19
<i>Akt Inhibition</i> .....	20
<i>mTOR Inhibition</i> .....	20
<b>CONCLUDING REMARKS</b> .....	21
<b>LIST OF ABBREVIATIONS</b> .....	22
<b>CONSENT FOR PUBLICATION</b> .....	23
<b>CONFLICT OF INTEREST</b> .....	23
<b>ACKNOWLEDGEMENTS</b> .....	23
<b>REFERENCES</b> .....	23
<b>CHAPTER 2 POLYMERIC NANOMEDICINES IN TREATMENT OF BREAST CANCER: REVIEW OF CONTEMPORARY RESEARCH</b> .....	36
<i>Farooq Ali Khan, Md. Rizwanullah, Ahmad Perwez, Mohammad Zaki Ahmad and Javed Ahmad</i>	
<b>INTRODUCTION</b> .....	37
<b>CHALLENGES IN TREATMENT OF BREAST CANCER</b> .....	37
<b>POTENTIAL OF POLYMERIC NANOMEDICINES IN TREATMENT OF BREAST CANCER</b> .....	39
<b>TARGETING IN TREATMENT OF BREAST CANCER</b> .....	41
Passive Targeting .....	41
Active Targeting .....	42
<b>DIFFERENT POLYMERIC NANOMEDICINES IN TREATMENT OF BREAST CANCER</b> .....	43
Polymeric Nanoparticles .....	43
Polymeric Micelles .....	47
Polymer-lipid Hybrid Nanoparticles .....	52
Dendrimers .....	54
<b>POLYMERIC NANOMEDICINE FOR GENE THERAPY IN BREAST CANCER</b> .....	58
<b>CONCLUDING REMARKS</b> .....	60
<b>LIST OF ABBREVIATIONS</b> .....	60
<b>CONSENT FOR PUBLICATION</b> .....	61
<b>CONFLICT OF INTEREST</b> .....	61
<b>ACKNOWLEDGEMENTS</b> .....	61
<b>REFERENCES</b> .....	61

<b>CHAPTER 3 TREATMENT OF LUNG CANCER IN THE NEW ERA</b> .....	67
<i>Girisha Maheshwari, Bhanu Pratap Chauhan, Shweta Dang and Reema Gabrani</i>	
<b>INTRODUCTION</b> .....	67
<b>SMALL MOLECULE-BASED INHIBITORS</b> .....	68
First Generation Inhibitors .....	70
Second Generation Inhibitors .....	71
Third Generation Inhibitors .....	71
<b>MONOCLONAL ANTIBODIES</b> .....	72
<b>NOVEL APPROACHES</b> .....	74
Epigenetic Therapies .....	74
MicroRNA .....	75
Tumor Suppressor MicroRNAs in Lung Cancer .....	75
Oncogenic MicroRNA in Lung Cancer .....	75
<b>NANOPARTICLE FORMULATIONS</b> .....	76
<b>PERSONALIZED MEDICINE</b> .....	77
<b>CONCLUSION</b> .....	77
<b>CONSENT FOR PUBLICATION</b> .....	78
<b>CONFLICT OF INTEREST</b> .....	78
<b>ACKNOWLEDGEMENTS</b> .....	78
<b>REFERENCES</b> .....	78
<b>CHAPTER 4 ORAL ADMINISTRATION OF CANCER CHEMOTHERAPEUTICS EXPLOITING SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM: RECENT PROGRESS AND APPLICATION</b> .....	83
<i>Javed Ahmad, Farooq Ali Khan, Mohammad Zaki Ahmad, Showkat Rasool Mir, Noor Alam and Saima Amin</i>	
<b>INTRODUCTION</b> .....	84
<b>ANTICANCER ORAL THERAPY</b> .....	85
<b>BIOPHARMACEUTICAL BARRIERS IN ORAL CHEMOTHERAPY</b> .....	86
<b>SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR ANTICANCER ORAL THERAPY</b> .....	88
Contemporary Research and Application .....	90
Recent Progress and Advancement .....	93
<i>Solidification Technique Transforming SNEDDS into Solid Dosage Forms</i> .....	94
<i>Challenges with Solidification Techniques</i> .....	95
<i>Strategies to Overcome the Challenges Associated with Solidification Techniques</i> ....	95
<b>CONCLUDING REMARKS</b> .....	96
<b>CONSENT FOR PUBLICATION</b> .....	96
<b>CONFLICT OF INTEREST</b> .....	96
<b>ACKNOWLEDGEMENTS</b> .....	96
<b>LIST OF ABBREVIATIONS</b> .....	96
<b>REFERENCES</b> .....	97
<b>CHAPTER 5 TARGETING APPROACHES FOR THE DIAGNOSIS AND TREATMENT OF CANCER</b> .....	105
<i>Shivani Saraf, Ankita Tiwari, Amit Verma, Pritish K. Panda, Sarjana Raikwar, Ankit Jain, Rupal Dubey and Sanjay K. Jain</i>	
<b>INTRODUCTION</b> .....	105
<b>DIAGNOSIS TECHNOLOGY</b> .....	107
<b>RECENT APPROACHES FOR THE TREATMENT OF CANCER</b> .....	111
Targeted Drug Delivery Carriers .....	111

<i>Liposomes</i> .....	111
<i>Nanoparticles</i> .....	113
<i>Nanoemulsion</i> .....	114
<i>Hydrogel</i> .....	115
<i>Gene Therapy</i> .....	116
<i>Aptamer Based System</i> .....	117
<i>Antibody Based System</i> .....	118
Stimuli Sensitive Drug Delivery Systems .....	120
<i>pH Sensitive Drug Delivery Systems</i> .....	121
<i>Temperature Sensitive Drug Delivery Systems</i> .....	122
<i>Magnetic Sensitive Drug Delivery Systems</i> .....	122
<i>Redox Sensitive Drug Delivery Systems</i> .....	123
<i>Photosensitive Drug Delivery Systems</i> .....	123
Herbal Drug Approaches .....	124
<b>CONCLUSION</b> .....	127
<b>CONSENT FOR PUBLICATION</b> .....	127
<b>CONFLICT OF INTEREST</b> .....	128
<b>ACKNOWLEDGEMENTS</b> .....	128
<b>REFERENCES</b> .....	128
<b>SUBJECT INDEX</b> .....	35;



## PREFACE

Despite tremendous development in our understanding of different types of cancer at biochemical and genetic levels, prevention, diagnosis, and treatment is still far from perfect. Based on the histopathological heterogeneity and remarkable genetic complexities of cancer, research on this disease has emerged as a truly interdisciplinary science. From biomarker identification for diagnosis and diseases progression monitoring to personalized treatment, the research is spread over a wide range of fields and disciplines. This book series “*Frontiers in Anti-Cancer Drug Discovery*” is, therefore, aimed to provide comprehensively written review articles on carefully selected topics in this important field. Volume 11 of the book series contains five (5) chapters covering target identification to new classes of anticancer therapies, each contributed by eminent experts.

The review contributed by Neri *et al.* focusses on the importance of targeting phosphoinositide 3 kinases (P13Ks), their downstream mediator Akt and the mammalian target of rapamycin (mTOR) as targets for drug discovery against the acute lymphoblastic leukemia (ALL). They have included examples of small molecular inhibitors of P13Ks/Akt/mTOR as targeted drug candidates. Javed *et al.* have reviewed recent researches on polymeric nanomedicine for the treatment of breast cancers. The results of preclinical studies on polymeric nanomedicines in terms of target specificity, improved bioavailability and safety *via* their passive and active modes of action are presented. Lung cancers (non-small cell lung cancer and small cell lung cancer) are among the most aggressive cancer types with high mortality. Gabrani *et al.* review recent developments in the treatment of lung cancers, including EGFR tyrosine kinase inhibitors (TKIs), inhibitors of imbalance microRNA, and immunotherapy. Saima *et al.* have contributed a comprehensive chapter on the recent advancements in the applications of self-nanemulsifying drug delivery system (SNEDDS) for cancer chemotherapeutics. SNEDDSs offer improved bioavailability and greater tolerability as oral anticancer drug delivery vehicles. Last but not the least, Jain *et al.* focus on exciting advances in novel targeting approaches for the prevention, diagnosis and treatment of cancers. This includes theranostics based systems for diagnosis coupled cancer therapies.

The above review articles by prominent researchers in the field of cancer research directed towards anticancer drug discovery should be of great interest to research scholars. We are grateful to all the authors for their excellent and scholarly contributions to the 11<sup>th</sup> volume of this internationally acclaimed ebook series. The Editorial team of Bentham Science Publishers deserves appreciation for the efficient processing and timely management of this publication. The coordination and liaison by Ms. Fariya Zulfiqar (Manager Publications), under the leadership of Mr. Mahmood Alam (Director Publications) is gratefully acknowledged. We also hope that like the previous volumes of this book series, the current compilation will also receive wide readership, and appreciation.

**Prof. Dr. Atta-ur-Rahman, FRS**  
Honorary Life Fellow  
Kings College  
University of Cambridge  
Cambridge  
UK

**Prof. Dr. M. Iqbal Choudhary**  
H.E.J. Research Institute of Chemistry  
International Center for  
Chemical and Biological Sciences  
University of Karachi  
Karachi  
Pakistan

## List of Contributors

<b>Ahmad Perwez</b>	Genome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India
<b>Amit Verma</b>	Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India
<b>Ankita Tiwari</b>	Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India
<b>Ankit Jain</b>	Institute of Pharmaceutical Research, GLA University, NH-2, Mathura-Delhi Road, Mathura (U.P.) 281 406, India
<b>Bhanu Pratap Chauhan</b>	Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India
<b>Carolina Simioni</b>	Department of Medical Sciences, University of Ferrara, Ferrara, Italy
<b>Daniela Milani</b>	Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
<b>Farooq Ali Khan</b>	Sri Indu Institute of Pharmacy, Hyderabad, India
<b>Giorgio Zauli</b>	Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy LTTA Center- Flow Cytometry and Cell Sorting service, University of Ferrara, Ferrara, Italy
<b>Girisha Maheshwari</b>	Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India
<b>Javed Ahmad</b>	Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia (KSA)
<b>Luca M. Neri</b>	Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy LTTA - Electron Microscopy Center, University of Ferrara, Ferrara, Italy
<b>Md. Rizwanullah</b>	Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
<b>Mohammad Zaki Ahmad</b>	Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia (KSA)
<b>Noor Alam</b>	Post-Graduate Department of Botany, Purnea University, Bihar, India
<b>Pritish K. Panda</b>	Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India
<b>Reema Gabrani</b>	Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India
<b>Rupal Dubey</b>	School of Pharmacy and Research, People's University, Bhopal (M.P.)462037, India
<b>Saima Amin</b>	Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
<b>Sanjay K. Jain</b>	Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India

- Sarjana Raikwar**      Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India
- Showkat Rasool Mir**      Phytopharmaceutical Research Laboratory, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
- Shweta Dang**      Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India
- Shivani Saraf**      Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India

# PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies

Carolina Simioni<sup>1</sup>, Giorgio Zauli<sup>2,3</sup>, Daniela Milani<sup>2</sup> and Luca M. Neri<sup>2,4,\*</sup>

<sup>1</sup> Department of Medical Sciences, University of Ferrara, Ferrara, Italy

<sup>2</sup> Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

<sup>3</sup> LTTA Center- Flow Cytometry and Cell Sorting service, University of Ferrara, Ferrara, Italy

<sup>4</sup> LTTA - Electron Microscopy Center, University of Ferrara, Ferrara, Italy

**Abstract:** Acute Lymphoblastic leukemia (ALL) comprises a subset of different hematologic neoplasms characterized by impaired proliferation of immature lymphoid cells in bone marrow and peripheral blood. Pediatric patients have experienced treatment success with 5- year overall survival rates approaching 90%, whereas ALL adult patients are associated with poorer survival. Therefore, the development of new targeted therapeutic protocols constitutes a primary need. Phosphoinositide 3-kinases (PI3Ks) and their downstream mediators Akt and mammalian target of rapamycin (mTOR) represent the main components of the PI3K/Akt/mTOR signaling network. It is a key regulatory signaling cascade which drives proliferation, survival and drug-resistance of cancer cells, and it is frequently up-regulated in the different T- and B-ALL subtypes. Serious and irreversible late effects from conventional therapy are a growing issue for leukemia survivors, both for adult and pediatric patients. Therefore, the need to develop targeted and personalized therapy protocols for the treatment of leukemias is mandatory. Recent diagnostic tools allow to design therapeutic protocols with increased target specificity towards PI3K/Akt/mTOR axis that represents a critical target for cancer therapy. This chapter will focus on how this pathway could constitute a paradigm for the development of therapeutic strategies and how effective the recent pharmacological Small Molecule Inhibitors (SMIs) can suppress leukemic cell growth.

**Keywords:** Acute Lymphoblastic Leukemia, Apoptosis, Autophagy, Cytotoxicity, PI3K/Akt/mTOR, Proliferation, Signal transduction, Small Molecule Inhibitors (SMIs), Survival, Targeted Therapies, Tyrosine Kinase Inhibitors (TKIs).

## INTRODUCTION

Neoplastic diseases such as solid tumors and leukemia hematological disorders

\* Corresponding author Luca M. Neri: Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; Tel; +39-0532-455940; E-mail: luca.neri@unife.it

contribute significantly to morbidity and mortality of the population worldwide [1 - 4]. Whereas, some cancers show declining incidences in part due to effective prevention programs, others such as ALL are increasing in incidence. This is in part due to the fact that as life expectancy is increasing, in parallel some ALL incidence increases as well.

Development of new targeted treatment strategies aiming to increase cure rates and to decrease side effects is essential to take care of this patient population. Fundamental bases for such developments are a complex knowledge on oncogenesis, and more specifically on leukemogenesis [5, 6]. Aberrantly activated signaling pathways have been identified in different cancer models leading to the development of specific drugs, targeted therapies and ameliorated cure rates.

An example of aberrantly activated signaling pathways or receptors that could contribute to the oncogenesis mechanism is, in colon cancer cells, the Epidermal Growth Factor Receptor (EGFR). This receptor is responsible for the activation of RAS/RAF/MAPK pathway [7]. Subsequently, EGFR inhibitors and anti-EGF antibodies were developed, improving treatment outcomes. Similarly, in renal carcinoma, abnormal activation of receptor tyrosine kinases has been identified, leading to an abnormal activation of the VEGF/RAF/RAS pathway [8]. Other multikinase inhibitors, such as Regorafenib for colon cancer or Cabozantinib for renal carcinoma and hepatocellular carcinoma, have been developed with the aim to increase survival and quality of life [9 - 11].

It has been reported that in ALL, and especially in the T-ALL subtype, the EGFR pathway inhibition enhanced anticancer drugs induced cell death [12]. But another signaling pathway that displays constitutive activation in ALL, leading to uncontrolled production of malignant cells and driving chemotherapy resistance is the PI3K/Akt/mTOR signaling network. PI3K/Akt/mTOR is one of the most frequently aberrant activated pathway, and the inactivation of the tumor suppressor gene Phosphatase and tensin homolog (PTEN) represents one of the causes of this network stimulation [13 - 16], thereby giving the cancer cell a survival advantage. Indeed, literature data indicate that genetic alterations in components of PI3K/Akt/mTOR network have a close relationship with the development of ALL, thereby contributing to leukemogenesis, and these evidences highlighted the importance of developing new targeted therapies against this signaling network, with the aim to better predict favorable outcomes in acute leukemia patients. In chronic myeloid leukemia (CML), activation of this pathway is correlated to BCR-ABL tyrosine kinase, found also in 25% of adult ALL and less in ALL childhood. Treatment of ALL adults is more difficult than in pediatric patients due to the higher frequency of this chromosome rearrangement, including also the development of a recently characterized

subtype, Philadelphia (Ph)-like ALL, with high expression of signaling tyrosine kinases, resulting in stimulation of Abl and the Janus kinase (JAK) signal transducer of activation (STAT) pathway (Jak/Stat) pathways [17]. As PI3K signaling is considered to be one of the decisive pathways for the transformation potential of BCR-ABL, and that it may play a role in causing one of the tyrosine kinase inhibitor (TKI) resistance, that is imatinib, the pharmacological combination of more than one targeted cascade inhibitor is necessary, as well as the association of drugs targeting the same pathway at multiple levels. Pediatric patients have better prognosis because of minimal residual disease (MRD) monitoring and the intensification of more targeted treatments that, in association also with recent PI3K/Akt/mTOR inhibitors, could overcome glucocorticoid (GC) treatment resistance, frequently observed in ALL pediatric patients.

The importance of targeting this signaling network will be discussed in this chapter, together with a detailed profile of the most recent PI3K/Akt/mTOR inhibitors, also known as SMIs, tested in preclinical and recent clinical studies for the treatment of ALL.

### **Acute Lymphoblastic Leukemia**

ALL is a malignant hematological disorder characterized by aberrant expansion and diffusion in blood and bone marrow of lymphoid progenitor cells. ALL is the most frequent cancer identified in children [18].

Based on morphology and cytogenetic profiles, two different types of ALL have been identified: B-acute lymphoblastic (B-ALL) and T-acute lymphoblastic (T-ALL).

The uncontrolled growth of B-cell precursors represents the main feature of B-ALL subtype [19] that, due to the differentiation level, can be classified as pro-B, common, precursor B (pre-B), and mature B-cell ALL.

T-ALL is an invasive blood neoplasm characterized by aberrant proliferation of transformed T-cell precursors, and accounts for approximately 15% and 25% of pediatric and adult ALLs, respectively [20 - 22]. The most specific surface marker for lymphoblastic T-cell is represented by CD31, others T-cell markers such as CD1a, and CD2-CD8 are differently expressed and are strictly dependent on the T-cell differentiation degree [23]. A novel subtype of T-cell ALL, ETP T-ALL, has recently been described [24], and is capable to differentiate into both T-cell and myeloid lineages. Indeed, these lineages share high similarities in the myeloid leukemic stem cells gene expression profiles [23]. Concerning the frequency, in children ETP-ALL has been reported to be present in 11% to 16% of T-ALL, while in adults ETP-ALL frequency ranges from 7,4% to 17% of T-ALL [25].

## Polymeric Nanomedicines in Treatment of Breast Cancer: Review of Contemporary Research

Farooq Ali Khan<sup>1,#</sup>, Md. Rizwanullah<sup>2,#</sup>, Ahmad Perwez<sup>3</sup>, Mohammad Zaki Ahmad<sup>4</sup> and Javed Ahmad<sup>4,\*</sup>

<sup>1</sup> Sri Indu Institute of Pharmacy, Hyderabad, India

<sup>2</sup> Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

<sup>3</sup> Genome Biology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India

<sup>4</sup> Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia (KSA)

**Abstract:** Among various types of cancers, breast cancer is one of the most frequent and major reasons of cancer death among women worldwide. It has the ability to spread to different organs of the body and develop metastases. Till date, chemotherapy is the most common option for the treatment of breast cancer. However, chemotherapy is not a very successful strategy to cure breast cancer and has decreased the survival rates according to the different breast cancer reports. The inability to deliver a specific drug to the target tissue/cell that causes toxicity to the normal healthy tissue/cell is the primary concern in the chemotherapy. Most of the chemotherapeutic drugs used in conventional chemotherapy have low aqueous solubility and high pre-systemic metabolism; therefore, they are biologically less available to the target location and affect normal healthy tissues/cell as well. Since the last decades, the development of nanoparticle technology has opened a new option in the successful treatment of breast cancer due to the various unique advantages offered by this nanoplatform. Among them, polymeric nanomedicines become the promising choice as the effective drug delivery system and provide great potential in the management of breast cancers as per the outcome of different preclinical studies. Polymeric nanomedicines may exhibit their anticancer efficacy either *via* passive or active targeting approach. Polymeric nanomedicines can be actively targeted by its surface conjugation to the breast cancer-specific targeting ligands. Active targeting of the nanomedicines has the ability to deliver the specific drug to the target site, therefore, healthy cells remain unaffected by active targeting. Moreover, polymeric nanomedicines have also been exploited in breast cancer treatment through gene therapy. This chapter summarizes the extensive literature of preclinical findings on polymeric nanomedicines exploited in the treatment of breast cancer.

\* **Corresponding author Javed Ahmad:** Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia (KSA); Tel: +966-550957371; E-mail: jahmad18@gmail.com

# These authors contributed equally to this work

Atta-ur-Rahman and M. Iqbal Choudhary (Eds.)  
All rights reserved-© 2020 Bentham Science Publishers

**Keywords:** Breast Cancer, Chemotherapy, Polymeric Nanomedicine, Targeted Delivery, Ligand, Preclinical Studies.

## INTRODUCTION

Human bodies are made up of more than  $10^{14}$  cells, and cancer can begin with one single cell or a group of cells that have mutations in them. The cell division and growth of cells are regulated by signals produced by the cells, and when such signals are faulty, then there is an uncontrolled, unregulated cell growth, which if unchecked by the immune system, leads to the formation of a lump or a tumor. There are more than two hundred types of cancers, classified according to the tissue and cell type of initial tumor. Cancer is known to be the major cause for human death worldwide and is a global pandemic as per the American Cancer Society, and according to the WHO, cancers account for more than 13% of all deaths each year, and this number is expected to reach 45% by 2030. Breast cancer is the most common cancer in women and is the second most common cancer overall. The American Cancer Society estimates about 271,270 new cases and 42,260 deaths in 2019 in the United States alone [1]. Around the globe, it affects more than 2.1 million women every year and is the leading cause of cancer-related deaths in women. Breast tissue consists of fat, duct, connective tissue, and glandular tissue. Breasts develop as a response to estrogens, progesterone, and other hormones such as growth hormone and insulin. Breasts grow mainly during puberty and in lactating women and during pregnancy. Breast cancer is majorly the carcinomas (adenocarcinomas) of epithelial cells lining the milk ducts. Early detection of breast cancer has improved the rate of survival, however, the current mortality rates remain high [2]. While the hallmarks of cancer are many, but from a pharmaceutical science perspective, the challenge is to make the existing few therapies that we have more effective. Chemotherapy remains one of the mainstays in our possible therapies in the fight against cancer. Polymeric nanomedicines are a pragmatic way forward to treat breast cancers as they offer specific targeting to different tumors, modifications and alterations in the nano device.

## CHALLENGES IN TREATMENT OF BREAST CANCER

Cancers as such are a complex disease, and amongst different forms of cancers, the breast cancer is a severe complex and heterogeneous disease where there are multiple tumor entities which have different clinical behaviors and have distinct histological patterns. Breast cancers usually metastasize into the lungs, liver, lymph, and brain, a significant number of women lose their lives as a result of metastatic breast cancer. Different types of breast special cancers such as basal-like carcinoma, Mucinous carcinoma, neuroendocrine carcinoma, micropapillary



carcinoma, papillary carcinoma, medullary carcinoma, acinic cell carcinoma constitute about 25% of breast cancers. The World Health Organization recognizes the existence of more than 18 different types of invasive breast cancers based on their histological type. Such a complex disease needs a multidisciplinary approach for its treatment and novel targets are being identified in these breast special cancers [3]. Breast cancer is defined based on the expression of receptors such as the HER-2 (Human Epidermal Growth Factor Receptor-2), ER (Estrogen Receptor) and PR (Progesterone Receptor). To target these receptors or any other targets, chemotherapy, hormonal therapy and radiotherapy seem to be a better choice of treatment, however, these are conventional methods which have only been able to kill differentiated cells but not able to completely remove the tumors [4].

Radiotherapy uses a high level of radiation and regresses the tumor growth in combination with chemotherapy and kills cells that are unseen during the surgery, preventing a recurrence. However, due to the high levels of radiation, there can be mild to severe side effects such as itching, peeling, soreness of the skin, loss of sensation in the breast tissue, and at the end of the treatment it may leave the skin weepy and moist [5]. Hormonal therapy, on the other hand, either adds or blocks hormones, female hormones play a role in the development of some breast cancer types mainly the estrogen and the progesterone, and hormonal therapy either lowers the levels of female hormones or completely blocks them thereby, preventing the development and growth of cancer cells. Tamoxifen a SERM (Selective Estrogen Receptor Modulator) has been commonly used in breast cancers since it is an anti-estrogen; it completely blocks the attachment of estrogen on the breast cancer cells' ER receptors. However, there are limitations with Tamoxifen as it increases the chances of resistance and also puts one at the risk of uterine cancer. Other agents which block the estrogen production such as Anastrozole causes bone fractures and joint pain [6].

Conventional dosage forms of chemotherapeutic agents lack selectivity in targeting and also cause cytotoxicity by non-targeted cells. Chemotherapy is given as either adjuvant or neoadjuvant chemotherapy, which is used after surgery to remove undetected breast cancer cells and before surgery to regress the tumors, which can be further removed by lumpectomy. Literature suggests that chemotherapy works best in a combination of different drugs and these come with side-effects such as the increased risk of infections, hair-loss, easy bleeding (because of the lesser number of platelets) mouth sores, nausea, vomiting and loss of appetite [7].

Another major limitation in the treatment of breast cancer is special types of breast cancers which are highly complex such as the basal-like breast cancer and

## Treatment of Lung Cancer in the New Era

Girisha Maheshwari, Bhanu Pratap Chauhan, Shweta Dang and Reema Gabrani\*

Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India

**Abstract:** The most frequent cancer related deaths have been associated with lung cancer. The subtypes, Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancers (SCLC), respond to chemical drugs and radiotherapy. NSCLC (60%) express membrane epidermal growth factor receptor (EGFR). The cell signalling pathway induced by EGFR has been attributed as a key reason for lung cancer progression. There are many FDA approved drugs available for the treatment which primarily includes EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, or EGFR neutralizing antibody, necitumumab. However, the reports suggest that EGFR can undergo further mutation in tyrosine kinase domain which makes the cells resistant to the ongoing treatment. Alternate signalling pathways may get activated accompanied by epithelial mesenchymal transition and imbalanced microRNAs that contribute towards resistance. Epigenetic changes in lung cancer also offer dynamic targets for cancer therapy. The agents targeting epigenetic changes can be combined with chemotherapy or other-directed therapy so that effective dose and hence toxicity is reduced with enhanced efficacy. Micro-RNAs are the largest class of the gene regulators that regulate the cancer genes. Inhibiting or replacing the cancer-causing miRNAs can be potential targets for cancer treatment. Researchers have also worked on immunotherapy drugs like nivolumab, pembrolizumab and atezolizumab, which reverse the inhibitory mechanism of the immune response. New findings from recent trails provide an optimistic perspective on the progress towards the better treatment of lung cancer.

**Keywords:** EGFR, Epigenetic, Immunotherapy, miRNA, PD-1/PDL-1, T790M mutation.

### INTRODUCTION

Lung cancer or lung carcinoma is defined as the uncontrolled proliferation of normal lung cells due to the genetic damage and it has the capacity to invade the neighboring tissues and metastasize the various cells of the body. Lung Cells sometimes behave abnormally and do not grow; these changes may lead to nonca-

\* Corresponding author Reema Gabrani: Jaypee Institute of Information Technology, A-10, Sector 62, Noida, Uttar Pradesh, India; Tel: +91-120-2594211; E-mail: reema.gabrani@jiiit.ac.in

ncerous tumors like hamartoma and papilloma. On the other hand, some changes that develops into cancerous behaviour with the ability to metastasize to different organs [1]. Today, in the 20<sup>th</sup> century, lung cancer is reported for the most deaths at the worldwide level and ranked high in both incidence and mortality. Lung cancer is subdivided into two forms: Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) where NSCLC are considered as the most prevalent form. Lung Cancer was considered a rare disease till the beginning of the 19<sup>th</sup> century whereas, thereafter increased incidents of lung cancer cases have been linked to rising in cigarette consumption worldwide [2]. Cigarette or tobacco contains dgp| q[a] pyrene, nicotine-derived nitrosamine ketone, 1, 3-butadiene and radioisotope of polonium-210, polonium among which at least 73 known carcinogens are identified and are the main reasons for lung cancer. Apart from smoking, the inheritance of gene polymorphism, radiations, asbestos and air pollution have also been found to be the major reasons for lung cancer [3].

The genetic DNA damage and epigenetic changes affect the cellular normal function, proliferation, repair, and apoptosis [4]. Molecular alterations in phosphoinositide 3-Kinase (PI3K)/Protein kinase B also known as AKT/mammalian target of rapamycin (mTor) pathways have been linked to lung cancer. Certain biomarkers like ProGRP (pro-gastrin-releasing peptide), CEACAM (carcinoembryonic antigen), EPCAM (epithelial cell adhesion molecule) and CYFRA 21-1 (cytokeratins) have been reported for their use in the diagnosis of lung cancer. Successful chemotherapy regimens were developed in 1970 after that new chemotherapy drugs for NSCLC include paclitaxel, docetaxel, vinorelbine, and gemcitabine [5]. Patients that were found with genomic aberrations are benefitted with the molecular targeted therapies. Some of the current therapies have been listed in Fig. (1). Epidermal Growth Factor Receptor (EGFR) overexpression has been predominantly linked to NSCLC lung cancer and has been related to poor survival and increased metastasis. Gefitinib and Erlotinib are the first generation reversible inhibitors that can completely block the adenosine triphosphate (ATP) binding site of EGFR and also inhibit the activity of tyrosine kinase. Unfortunately, there are many types of cancer that acquire resistance mutations and stop responding to the drugs. Although new drugs have been developed which are sensitive to the mutated versions of the EGFR, there is still a need to explore more compounds and drugs which could be effective against lung cancer [6].

### **SMALL MOLECULE-BASED INHIBITORS**

The discovery and optimization of small molecule inhibitors for the treatment of human diseases have been the major focus of the pharmaceutical industry for more than a century. Small-molecule kinase inhibitors are being intensively

pursued as new anticancer therapeutics. Broadly, there are three categories of inhibitors that are mentioned in Table 1. Currently, there are some of the known kinase inhibitors that target the ATP binding site with the kinase activation loop in the active (Type 1) or inactive (Type 2) conformations [19].

**Table 1. Recent FDA approved drugs used for the treatment of Non-small cell lung cancer [7].**

S.No	Name of Inhibitor	Year of Approval	Mechanism of Action	References
<b>First Generation Inhibitors</b>				
1.	Crizotinib (Xalkori)	March 11, 2016	An anti-cancer drug for Anaplastic lymphoma kinase (ALK) or ROS1 (c-ros oncogene-1) positive metastatic NSCLC.	[8]
2.	Erlotinib Hydrochloride (Tarceva)	May 14, 2013	It competes for the ATP binding site of EGFR and further inhibits phosphorylation of tyrosine kinase.	[9]
3.	Gefitinib (Iressa)	May 5, 2003	It blocks the ATP binding site which in turn inhibits the tyrosine kinase activity of EGFR.	[10]
<b>Second Generation Inhibitors</b>				
4.	Dacomitinib (Vizimpro)	September 27, 2018	Dacomitinib is used for the first-line treatment for metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.	[11]
5.	Afatinib Dimaleate (Gilotrif)	January 12, 2018	Afatinib is used to treat metastatic NSCLC where tumors have non-resistant EGFR mutations.	[12]
6.	Alectinib (Alecensa)	November 6, 2017	Alectinib is used as an oral drug to block the activity of ALK to treat NSCLC.	[13]
7.	Ceritinib (Zykadia)	May 26, 2017	Ceritinib is used for the treatment of ALK-positive metastatic NSCLC.	[14]
8.	Brigatinib (Alunbrig)	April. 28, 2017	Inhibitor for metastatic NSCLC having alteration in ALK gene.	[15]
<b>Third Generation Inhibitors</b>				
9.	Lorlatinib (Lorbrena)	November 2, 2018	ALK-positive metastatic NSCLC resistant to crizotinib/ alectinib or ceritinib.	[16]
10.	Osimertinib Mesylate (Tagrisso)	March 30, 2017	Irreversible inhibitor, targets metastatic EGFR T790M mutation harboring NSCLC.	[17]
11.	Olmotinib (Olita)	May 2016	Irreversible TKI binds tyrosine kinase domain of mutant EGFR.	[18]

## Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application

Javed Ahmad<sup>1</sup>, Farooq Ali Khan<sup>2</sup>, Mohammad Zaki Ahmad<sup>1</sup>, Showkat Rasool Mir<sup>3</sup>, Noor Alam<sup>4</sup> and Saima Amin<sup>5,\*</sup>

<sup>1</sup> Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, KSA

<sup>2</sup> Sri Indu Institute of Pharmacy, Hyderabad, India

<sup>3</sup> Phytopharmaceutical Research Laboratory, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

<sup>4</sup> Post-Graduate Department of Botany, Purnea University, Bihar, India

<sup>5</sup> Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

**Abstract:** The delivery of cancer chemotherapeutics has shifted dramatically in the last two decades from parenteral to oral administration. Improved patient compliance, drug tolerability, ease of administration, and potential effectiveness for oral therapy relative to intravenous administration have appeared as the main reasons to use cancer chemotherapeutics through the oral route of administration. However, most of the cancer chemotherapeutics show very poor oral absorption due to the drug's physicochemical characteristics, stability, and biological barrier (multidrug efflux proteins: P-glycoproteins) present in the GI tract. With advanced research in homolipids and heterolipids as excipients, lipid-based formulations were exploited to enhance the oral efficacy of poorly absorbable cancer chemotherapeutics in recent years. Self-nanoemulsifying drug delivery system (SNEDDS) is the highly developed strategy of emulsion dependent drug delivery systems and relies on the GI fluids for the formation of nanoemulsion inside the *in vivo* system. The advancement in the field of biocompatible lipid and their derivatives in addition to finding on pharmaceutical excipients such as oil, surfactants, co-surfactants having P-gp modulating potential further extend the interest in SNEDDS for delivery of cancer chemotherapeutics through oral administration. This chapter provides a comprehensive discussion about contemporary advancement in the application of SNEDDS for oral delivery of cancer chemotherapeutics.

\* **Corresponding author Saima Amin:** Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India;  
E-mail:samin@jamiyahamdard.ac.in; daneshyarsaima@yahoo.com

**Keywords:** Cancer Chemotherapeutics, Nanoemulsion, Oral Absorption, P-Glycoproteins, SNEDDS.

## INTRODUCTION

Cancer is a disease that occurs after numerous mutagenesis steps, permitting cancerous cells to develop uncontrollably [1]. Cancer is a leading cause of global mortalities. The cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. The diagnoses estimated for different cancers are: cancer of lung (2.1 million), breast (2.1 million), colorectal (1.8 million), prostate (1.3 million), and stomach (1.0 million) [2]. Breast cancer is the most common form of cancer in women globally and is rising mainly in developing countries where most of the cases are diagnosed in later stages [3]. The recent data from the World Health Organization suggests a 45% increase in the deaths caused due to cancer by 2030, of which 70% would be in developing countries like India [2]. Owing to these figures, there is a growing concern to treat this deadly disease. Presently, the technologies have made huge development but accurate therapy is still a challenge. Existing cancer treatments can be widely classified into two groups: cytotoxic therapies and molecular targeted drug delivery [4, 5]. Except for a few cancer types, where the treatment involves hormonal therapy or immunotherapy, cytotoxic agents remain the major form of chemotherapy for cancer [6]. Cytotoxic agents are a diverse class of compounds that are used in cancer therapy as they are toxic to cells that grow and divide quickly. Due to the fast growth and proliferation of cancerous cells, they are favorably killed by these agents. The preferred routes of administering these cytotoxic agents are through intravenous bolus or infusion, usually in the form of a drug solution. They have been used for a long time and the development of several multi-drug treatment regimens improved their clinical success. However, there is still the case of treatment failure [7, 8]. There is often an enormous and erratic protein binding of cytotoxic agents with body tissue and serum protein when given through traditional mode, only a small portion of the cytotoxic agents reach the tumor site [9]. This generally reduces the therapeutic efficacy and increases the systemic toxicity of the drug. Cytotoxic agents are supposed to kill only the cancer cells; however, they also end up killing noncancerous cells such as the ones which quickly divide, *e.g.* bone marrow cells. There is a regular occurrence of normal tissue toxicities even when the dose of anticancer agents remains standard. The significant challenge to effective cancer treatment is the poor drug specificity in terms of biodistribution and also at the cellular levels. The patients' quality of life and the overall life expectancy relates directly to the targeting ability of cytotoxic agents. Systemic administration through intravenous bolus or infusion sometimes leads to side effects which can be at times so intense, that the patient has to discontinue

the therapy, even before the drug could kill cancer cells [10]. There is an evolution of new anticancer agents and also the development of new methods to effectively administer old drugs.

## ANTICANCER ORAL THERAPY

In oncology, medicines as chemotherapy are mostly delivered intravenously contrasting the majority of biomedical disciplines [11, 12]. There has been a dramatic shift in the administration of chemotherapeutic agents, they are now given orally differing from the traditional parenteral route. However, the administration of cancer chemotherapeutics has shifted remarkably in the past 15 years from parenteral to oral administration [13, 14]. During recent times, the therapeutic trends have been observed by a continuous growth in the availability of oral cytotoxic drugs with >20 oral anti-cancer drugs presently approved for application in the United States and Europe [15 - 17]. It has mostly been the preference of patients to choose oral therapy relative to intravenous administration simply because of ease of administration and home-based therapy. It is also required that the toxicities associated with oral therapy should not be higher than intravenous therapy and the efficacy should be the same. Improved compliance, tolerance, ease of administration, and potential efficacy for oral therapy relative to intravenous administration have appeared as the major cause to use cancer chemotherapeutics through oral delivery. Compliance is vital for oral therapy because it decides the dose-intensity of the therapy and eventually efficacy and toxicity of the therapy. A lot of surveys indicate that maximum patients favor oral therapy to intravenous therapy [18 - 20]. Liu and group found that 89% of patients favor oral therapy rather than intravenous. It is primarily for the convenience of a home-based therapy (57% of patients), thereby escaping the insertion of a venous catheter (55% of patients) [18]. Other reasons were the negative earlier experiences with intravenous administration and a lesser access rate to the oncology service. The oral administration of cytotoxic agents provides longer drug exposure when compared to intermittent intravenous infusion. The drug exposure is dependent on exponential factors which are concentration and time. A drug with shorter  $t_{1/2}$  achieves better exposure time when given as a nonstop infusion. The exposure time has profound effects on drug toxicities and efficacy. An added advantage of oral chemotherapy is the decrease in the utilization of various resources for inpatient and ambulatory care services. There is also an improved quality of life with oral chemotherapy. Despite their numerous advantages for convenience and patient compliance, there are however potential challenges with the oral use of chemotherapeutic agents, which clinicians are desired to be aware of and take necessary steps to circumvent them or mitigate them [21 - 23]. Lastly, keeping in mind the rising prices of anticancer therapy,

## Targeting Approaches for the Diagnosis and Treatment of Cancer

Shivani Saraf<sup>1</sup>, Ankita Tiwari<sup>1</sup>, Amit Verma<sup>1</sup>, Pritish K. Panda<sup>1</sup>, Sarjana Raikwar<sup>1</sup>, Ankit Jain<sup>2</sup>, Rupal Dubey<sup>3</sup> and Sanjay K. Jain<sup>1,\*</sup>

<sup>1</sup> *Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India*

<sup>2</sup> *Institute of Pharmaceutical Research, GLA University, NH-2, Mathura-Delhi Road, Mathura (U.P.) 281 406, India*

<sup>3</sup> *School of Pharmacy and Research, People's University, Bhopal (M.P.) 462037, India*

**Abstract:** Cancer is a multi-factorial disease that necessitates a multi-modality therapeutic approach to accomplish a favorable outcome. Recently, theranostic based systems have been introduced for the diagnosis coupled cancer therapy. The development of targeted novel drug/gene delivery approaches for safe and efficacious treatment of cancer is an emerging arena that includes liposomes, nanoparticles, nanoemulsion, gene therapy, immunosuppressant therapy, herbal bioactive loaded nanocarriers and stimuli sensitive systems (pH, temperature, ultrasound, redox potential, hypoxia and magnetic). Advancements in molecular biology have rendered a wide range of targeting moieties (ligands) and a meticulous understanding of the cancer biology is under extensive exploration for the selection of appropriate targets for cancer treatment. The outcomes of various clinical studies of nanocarriers depict an improvement in the anticancer efficacy and reduction in side effects. This chapter is an assemblage of advances in the novel targeting approaches that enable the cancer prevention, prediction, diagnosis and treatment.

**Keywords:** Cancer, Diagnosis, Liposomes, Nanocarriers, Nanoparticles.

### INTRODUCTION

Tumor growth is a dynamic and complex process. Several factors such as complex angiogenesis, suppression of apoptosis, uncontrolled proliferation, escape from growth suppressor, increased invasion and metastasis, altered metabolism and evaded immune destruction may be involved in tumor growth and

\* **Corresponding author Sanjay K. Jain:** Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar (M.P.) 470 003, India; Tel: +91-7582- 225782; E-mail: drskjainin@gmail.com



dissemination [1, 2]. The tumor microenvironment (TME) consists of different cellular and non-cellular elements. The TME contains various non-malignant cells such as immune cells, bone marrow derived cells, inflammatory cells, extracellular matrix and tumor vasculature cells like cancer associated fibroblasts, endothelial cells and pericytes [3]. The stromal cells are recruited and stimulated by cancer cells. Stromal cells activate the biological signals and enhance the growth of fibroblasts which synthesize the chemokines, growth factors and adhesion molecules. The tumor stroma plays an important role in tumor metastasis and increases the capability to invade another cell. The cancerous cells are hypoxic in nature. Diffusion-limited hypoxia is caused due to restricted tumor vasculature since the tumor cells are distant from closest capillary as compared to the healthy cells ( $>100\ \mu\text{m}$ ) [4]. Due to the variation in oxygen delivery in blood vessels of tumor cells and oxygen consumption by cancer cells, there is a variation in their distance from blood vessels at which hypoxia occurs. Hypoxic condition in cancer cells causes stimulation of genes (hypoxia inducible factors 1 mediated) that are linked with angiogenesis process and cell survival. Such gene expressions may cause enhanced cell proliferation with modulated biochemical pathways which may resist the drug delivery [5]. Hypoxic areas of tumor cells have a reduced nutrient supply like glucose and amino acids. This is since cancer cells frequently utilize glycolysis to produce lactate in order to attain energy needed for cell survival and proliferation instead of oxidative metabolism, which efficiently leads to the generation of  $\text{CO}_2$  and carbonic acid. Reduced metabolism and clearance of these acidic components cause low interstitial pH, which is another feature of tumors [6, 7]. Nanotechnology has been the area of interest over the last decade for developing precise carrier as it offers numerous benefits to overcome the limitations of conventional drug delivery system [8, 9]. It is a very promising platform for the treatment and diagnosis of cancer because it enters into the cells at molecular level. The nanotechnology is divided into different types like passive targeting, active targeting and stimuli responsive targeting. In case of passive targeting, the nanoparticles are preferentially retained into the tumor due to enhanced permeability and retention effect whereas in active targeting, the drug is preferentially delivered to the site of action [10]. Nanoparticles can be designed through various modifications such as changing their size, shape, chemical and physical properties, and so forth, to program them for targeting the desired cells. The nanocarriers are anchored with some ligands or antibodies for active targeting of drug. The target moiety facilitates the recognition of nanocarriers either by ligand receptor interaction or antibody-antigen recognition [11]. Nanocarriers have three basic components (i) chemotherapeutic agents (ii) targeting agents (ligand or antibody) and (iii) carriers (liposomes, nanoparticles, niosomes, dendrimers, *etc.*) [12 - 14]. Nanocarriers are usually made up of natural and synthetic polymers and lipids [15]. Accelerated

clearance of nanocarriers from blood by reticulo-endothelial system uptake is the major drawback of novel drug delivery. Various approaches have been investigated to avoid the RES uptake and prolong the retention of nanocarriers in blood. The surface of nanocarriers is coated with hydrophilic polymers like polyethylene glycol (PEG), poloxamers, polysaccharides and poloxamines to avoid the elimination of carriers from opsonization. This phenomenon is known as “cloud” effect [16, 17]. The TME displays some unique features which can be used for active targeting of drug to the cancer cells. Cancer cells overexpress some receptors which can be utilized for active drug targeting. The ligands can be conjugated with nanocarriers which selectively bind to the receptor on tumor cells and internalized by receptor mediated endocytosis. Numerous studies are carried out to investigate interaction between ligand and receptor utilized for clinical use [18]. Further, stimuli sensitive nanocarriers came forth with recent advancements in nanotechnology. Several stimuli sensitive drug delivery systems have been used for the treatment of cancer like pH sensitive, temperature sensitive, photo sensitive, magnetic field responsive and hypoxia responsive drug delivery systems. They are made by stimuli responsive materials which change their properties in response to variations in the environment. They selectively release the drug in the presence of external or internal stimuli [19, 20]. The emerging growth of nanotechnology provides the opportunity to develop the multifunction delivery systems that allow the simultaneous detection, diagnosis, and treatment of tumor [21]. The theranostic system containing both diagnostic agent and drug in a single carrier can monitor the localization of drug at a specific site, visualize their biodistribution and assess therapeutic efficacy [22]. Ideal theranostic systems should: (i) localize into the cancer cells, (ii) visualize the biochemical and morphological changes of tumor cells, (iii) selectively deliver the drug to the target site without affecting the normal cells and (iv) be safe and biodegradable [23, 24].

## DIAGNOSIS TECHNOLOGY

“Theranostics” is a new pharmaceutical strategy merging both diagnosis and treatment in a single delivery system. The theranostic nano-carrier contains therapeutic agents and diagnostic entities in a single system like liposomes or nanoparticles which monitor the treatment efficiency by proper imaging of disease and beneficial for more precise treatment of various complex diseases (Fig. 1). The field of theranostic is uprising after the development of nanotechnology based carriers like nanoparticles, liposomes, dendrimers, micelles, and carbon nanotubes. It is one of the most potential approaches for targeting the cancer and providing the individualized treatment for cancer patients [25 - 27].

## SUBJECT INDEX

## A

- Aberrant 7, 73  
 activity 7  
 EGFR expression 73  
 Ability 36, 48, 49, 53, 55, 58, 60, 68, 72, 88,  
 91, 116, 117, 118, 119, 126  
 distinct 117  
 enhanced 53  
 inducing 126  
 Absorption 86, 87, 88, 92, 95, 109, 123  
 complete 123  
 systemic 86, 87  
 Absorptive cells, intestinal 87  
 Accelerated cell apoptosis 51  
 Acid 42, 44, 48, 49, 51, 53, 106, 109, 110,  
 111, 114, 122, 125, 126  
 acrylic 122  
 carbonic 106, 122  
 gambogic 48, 51, 53  
 hyaluronic 44, 109, 110, 126  
 -labile carbamate linkage 114  
 linoleic 49  
 nucleic 42, 111, 114  
 polyarabic 109  
 -targeted liposomes 111  
 ursolic 125  
 Actin rearrangement 7  
 Activated pathway, aberrant 2  
 Activating JAK mutations 4  
 Activation 2, 3, 6, 7, 8, 9, 13, 14, 18, 70, 73,  
 74, 125, 126  
 abnormal 2  
 caspase 126  
 consequent 6  
 constitutive 2  
 feedback 13  
 increased downstream 6  
 Active 42, 72  
 immunotherapy targets 72  
 targeting of nanomedicine 42  
 Activity 5, 6, 7, 13, 14, 17, 18, 20, 40, 55,  
 111, 112, 119, 125  
 anti-metastatic 40  
 cytostatic 13  
 demonstrated high antiproliferation 55  
 displayed decreased PTEN 7  
 minor immunosuppressive 13  
 Agents 38, 41, 42, 67, 73, 74, 77, 78, 84, 86,  
 107, 109, 113, 115, 116, 117, 120, 123,  
 124, 125, 127  
 anti-angiogenic 73, 113  
 commercial gadolinium-based contrasting  
 109  
 herbal 116, 125, 127  
 natural 127  
 novel 41  
 reducing 123  
 surface-active 86  
 therapeutic 42, 77, 107, 115, 123  
 Air pollution 68  
 Akt downstream targets 11  
 Akt inhibition 10, 11, 12, 19, 20  
 targeted 12  
 ALK 69, 73  
 gene 69  
 mutations 73  
 -positive metastatic NSCLC 69  
 Alternating magnetic field (AMF) 116  
 American cancer society 37  
 Amino terminal fragment (ATF) 110  
 Anaplastic lymphoma kinase (ALK) 69, 74,  
 77  
 Androgen receptor (ARs) 117  
 Angiogenesis 41, 52, 70, 73, 105  
 complex 105  
 Angiogenesis process 106  
 Animal oils 88  
 Anti-angiogenic activity 52  
 Anti-angiogenic effect 73  
 Antibody 118, 119, 120  
 based system 118  
 -dependent cellular cytotoxicity (ADCC)  
 119, 120  
 drug conjugates (ADCs) 120  
 Anticancer activity 40, 49, 114, 126  
 effective 49  
 multimodal 40

Anticancer drugs 58, 86, 87, 91, 93, 122, 123, 127  
 lipophilic 91  
 Anti-cancer Therapeutics 45, 46, 47, 50, 51, 53, 54, 56, 57, 58, 88  
 lipophilic 88  
 Anticancer therapy 85  
 Anti-EGF antibodies 2  
 Antigens 72, 68, 78, 119  
 associated 72  
 carcinoembryonic 68  
 targets TRAIL R1 119  
 Anti-HER2 antibody 123  
 Anti-leukemic 11  
 action 11  
 Antisense 57, 59, 76  
 oligodeoxynucleotides 57  
 oligonucleotides results 76  
 technology 59  
 Anti-synergistic effect 14  
 Anti-transferrin receptor 112  
 Antitumor 44, 45, 48, 91, 116, 122, 125  
 antibodies 116  
 effects 44, 45, 48, 122  
 efficacy 44  
 properties 91  
 treatment efficiency 125  
 Antitumor activity 48, 52, 56, 116, 127  
 improved 52  
 increased 56  
 Antitumoral action 13  
 Apoptosis 5, 6, 7, 8, 9, 10, 11, 13, 14, 43, 44, 45, 49, 53, 54, 55, 58, 75, 76, 116, 125, 126  
 accentuated 14  
 activity 116  
 caspase-dependent 10  
 caspase-independent 14  
 cellular 11  
 higher 49, 53, 54  
 increased 54  
 induced 116  
 inducing 9  
 inhibitor survivin 59  
 reduced 58  
 Aptamers 39, 42, 56, 111, 117, 118  
 advanced DNA 118  
 Arematrix-based systems 43  
 Asthma 73, 126  
 ATP 56, 68

aptamers 56  
 ATP binding 9, 124  
 -binding sites of mTORC1 and mTORC2 9  
 cassette 124  
 ATP binding site 69  
 of EGFR 69  
 ATP-competitive 11, 12  
 dual PI3K/mTOR drugs 12  
 inhibitor 11  
 Autophagy 1, 7, 9, 10, 11, 13, 14, 18, 126  
 induced 9  
 process 7

## **B**

B-cell 3, 4, 14, 120  
 mature 3  
 leukemias 120  
 lymphomas 120  
 precursors 3  
 proliferation 4  
 receptor (BCR) 14  
 Bifunctional conjugation of nanoparticles 43  
 Binding 47, 70, 71, 72, 74, 84  
 erratic protein 84  
 known intracellular 47  
 Biomarkers 5, 68, 75, 117  
 new genetic 5  
 putative cancer 75  
 Biotin receptor 42  
 Blocks, immune checkpoint inhibitors 72  
 Blood vessels 41, 42, 106  
 formed 41  
 healthy 41, 42  
 Boronic acid 126  
 BRCA1 expression 46  
 Breast cancer 36, 37, 38, 39, 41, 43, 44, 45, 46, 48, 49, 50, 53, 54, 55, 56, 58, 59  
 basal-like 38, 39  
 cure 36  
 invasive 38  
 metastasis 55  
 metastatic 37, 48  
 resistant 49, 54, 56  
 therapy 39, 44, 46, 49, 56  
 treatment of 36, 37, 38, 39, 41, 43, 45, 50, 53, 56, 58, 59  
 Breast cancer cells 38, 44, 47, 48, 53, 55, 56, 109  
 human 56

- metastatic 48, 55
  - non-metastatic 48
  - positive 55
  - undetected 38
- C**
- Camptothecin analogues 124
  - Cancer 1, 2, 12, 13, 14, 20, 36, 37, 38, 48, 53, 58, 67, 76, 77, 84, 90, 105, 106, 108, 109, 110, 111, 112, 114, 115, 116, 117, 118, 119, 120, 121, 125, 126, 127
    - chemotherapy 118
      - cervical 119
    - colon 2, 114, 117, 118, 125, 126
    - deaths 36, 84
      - endometrial 125
    - genes 58, 67
    - growth profiles 114
    - liver 126
    - malignancies 118
      - metastatic genitourinary 112
    - pancreatic 14, 20, 110, 115
    - prostate 110, 117
    - resistant 48
    - special 37, 38
      - therapeutics 76, 90, 121
    - therapy 1, 53, 67, 84, 111, 112, 114, 119, 120, 127
  - Cancer cell 51, 72, 117, 119
    - biology 119
    - cytotoxicity 51
    - growth 72
    - invasion 117
    - higher breast 51
  - Cancer chemotherapeutics 83, 85, 86, 88, 96
    - administration of 85, 96
    - bioavailable 88
    - delivery of 83
  - Cancerous cells 84, 106, 116
    - permitting 84
  - Capsaicin 124, 125
    - herbal alkaloid drugs 124
  - Carbodiimide reaction 55
  - Carbon dioxide gas 122
  - Carcinogenic conditions 120
  - Carcinomas 2, 37, 38, 74, 120
    - acinic cell 38
    - basal-like 37
    - embryonal 120
    - medullary 38
    - neuroendocrine 37
    - papillary 38
    - renal 2
      - squamous cell 74
  - Cardiotoxicity, reduced 58
  - Cargo, tumor-killing 55
  - Cascade 15, 55, 71
    - generating cell death 55
    - signal 71
  - Cell cycle 5, 8, 14, 43, 49, 75, 76, 126
    - arrest 8, 43, 49, 75
    - blockade 14
    - progression 5
  - Cell death 2, 8, 11, 13, 14, 16, 57, 72, 76, 126
    - dependent 13
      - induced 2
    - marked 16
      - programmed 11, 14
      - programmed tumor 72
  - Cell growth 1, 6, 8, 13, 16, 37, 72, 75
    - abolished 16
    - control cancer 72
    - suppressing tumoral 13
    - suppress leukemic 1
    - unregulated 37
  - Cell lines 13, 44, 48, 54, 55, 57, 59, 76, 111, 117, 124
    - human breast cancer 54, 59
      - metastatic cancer 57
      - negative human breast 55
      - positive human breast cancer 55
    - prostate cancer 111
  - Cells 14, 36, 37, 38, 39, 45, 53, 57, 58, 59, 67, 72, 73, 74, 87, 106, 112, 115, 116, 117, 118, 124
    - bronchi 73
    - carcinogenic 118
    - endothelial 73, 106, 124
    - healthy 36, 45, 53, 72, 106, 112, 115
    - immune 106
    - inflammatory 106
    - intestinal 87
    - metastatic 117
    - non-malignant 106
    - non-targeted 38
    - single 37
    - tumour 116
  - Cellular internalization 44, 55
    - higher 55

- Cellular processes 70, 75
  - basic 75
- Cellular progression regulator 7
- Cellular uptake 43, 44, 46, 49, 50, 51, 52, 55, 59, 91, 110, 112, 115, 122, 125
  - complex showed higher 122
  - higher 43, 44, 50, 55
  - increased 49, 51
  - insufficient 125
- Cell uptake 45, 51, 53, 114, 121
  - displayed higher 114
  - higher 45, 51, 53
  - increased 121
- Chemo-photothermal therapy 49
  - synergized 49
- Chemotaxis assays 55
- Chemotherapeutics 41, 74, 86
  - normal 74
  - traditional 41
- Chemotherapy 2, 15, 21, 36, 37, 38, 39, 67, 74, 75, 84, 85, 86, 113, 115, 122, 124, 127
  - conventional 15, 21, 36, 124, 127
  - cycles 113
    - high-intensity 21
  - local 115
  - neoadjuvant 38
  - oral 85, 86
  - platinum-containing 74
    - resistance 2
- Chimeric antibody 119, 120
- Chinese hamster ovary (CHO) 119
- Chitosan 44, 46, 51, 56, 111, 121, 126
  - glycol 121
  - low molecular weight 111
  - nanoparticles 46, 126
    - PLGA micelles 51
    - systems 44
    - thiolated 44
- CHO cells 56
- Chromatin 5, 74
  - remodelling 74
  - structure modifiers 5
- Chromosomal 2, 4
  - lesions 4
  - rearrangement 2
- Chronic lymphocytic leukemia (CLL) 9, 18, 119, 120
- Chronic myeloid leukemia (CML) 2, 15
- Chrysin's effects 44
- Cigarette consumption 68
- Circulating tumor cells (CTCs) 118
- Circulation 48, 87, 121
  - entero-hepatic 87
  - plasma 48
- Cisplatin 73, 74, 86, 91, 92
  - free 92
  - minimized 91
- Cleavable bond 123
- Clonogenic assay 116
- Coating, polyarabic acid 109
- Colloidal systems 47
- Colon cancer cells 2
- Colorectal cancer 122, 125
  - metastatic 122
- Combination 3, 8, 9, 15, 16, 18, 20, 21, 38, 72, 73, 77, 112, 113, 122, 124, 125
  - pharmacological 3
  - synergistic 77, 124
- Combinational therapy 49
- Combination therapy 40, 78
- Complement dependent cytotoxicity (CDC) 119, 120
- Complexes 6, 7, 59
  - associated signaling 6
  - loaded chitosan  $\beta$ -cyclodextrin 59
- Concentration-dependent growth inhibition 54
- Conjugate 52, 57, 87, 111, 113, 120, 123
  - dendrimer LFC131 57
  - lipid 111
  - lipid-drug 87
  - lipid-PEG 52
  - nanoparticle-drug 113
  - recombinant 120
- Conserved family kinases 6
- Contemporary research and application 90
- Conventional 14, 38, 106
  - chemotherapy regimens 14
  - dosage forms of chemotherapeutic agents 38
  - drug delivery system 106
- Corn oil 90
- Cortical-medullary junction 18
- CpG-oligodeoxynucleotides function 55
- Cremophore 90, 92, 93
  - RH40 90, 92
- Crk protein 75
- Curcumin 48, 49, 50, 51, 91, 92, 93, 116, 125, 127
  - delivery 48, 125

liposomes 125  
 Cytogenetic profiles 3  
 Cytokine 16, 23, 58, 116  
   encoding immune-stimulatory 116  
   genes 116  
   inhibitory 58  
   receptor 16, 23  
 Cytoplasmic blebbing 125  
 Cytosine arabinoside cytarabine 11  
 Cytotoxic 9, 50, 72, 84, 85, 86, 87, 88, 90, 92,  
   109, 110  
   agents 84, 85, 86  
   drugs 87, 88, 90, 92, 109  
     oral 85  
   effects 9, 50  
   peptide 110  
   T-lymphocyte 72  
 Cytotoxic activity 11, 91, 92  
   significant 11  
 Cytotoxicity 45, 49, 91, 119  
   antibody-dependent cellular 119  
   increased cell 91  
   indicated 49  
   effect 45

## D

Daunorubicin-induced apoptosis 8  
 Degradation 4, 6, 42, 58, 59, 114  
   carbamate link 114  
   mediated 4  
   nuclease 58  
   proteasomic 6  
 Dendrimer conjugate 54, 55  
 Dendrimers 39, 40, 43, 54, 55, 56, 57, 58, 76,  
   106, 107  
   aptamers-based 57  
   branched oligoethylene glycol 56  
   conjugated 55  
   developed 54  
   grafted polyamidoamide 55  
   targeted 55  
   targeting 56  
   thermoreponsive 54, 56  
 Diagnosis 39, 76, 84, 105, 106, 107, 108, 109,  
   111, 118, 124, 127  
   antibody-based 118  
   early 127  
   effective 109  
   efficient 111

technology 107  
 Diagnostic 1, 107  
   agent 107  
   tools 1  
 Disease 3, 5, 9, 21, 37, 38, 68, 72, 73, 84, 105,  
   107, 108, 121, 124, 126  
   chronic obstructive pulmonary 73  
   complex 37, 38, 107  
   deadly 84  
   dermatological 126  
   heterogeneous 37  
   human 5, 68  
   minimal residual 3, 21  
   multi-factorial 105  
   rare 68  
 DNA 10, 68, 74, 75, 114, 117, 118  
   damage, genetic 68  
   methylation 74, 75  
   methyltransferase inhibitors (DNMTi) 74  
   nanoparticles 114  
   oligonucleotides 117, 118  
   synthesis 10  
 DNAzyme 58, 59  
   delivery 58  
   developed mRNA-cleaving 59  
 DNMT inhibitors 78  
 Dose-limiting toxicity (DLT) 20, 23, 112, 113  
 Downregulation 18, 46, 56, 59  
 DOX 46, 55, 56, 121, 122  
   and antisense oligonucleotide 46  
   controlled delivery of 56, 121  
   generation 55  
   release of 121, 122  
 Doxorubicin 9, 10, 19, 43, 59, 86, 87, 109,  
   110, 114, 116, 123, 125  
   delivery of 109, 116  
   loaded 114  
   pH-responsive 114  
   -resistant breast cancer cell line 59  
   sensitive 123  
 Drug delivery 40, 42, 43, 47, 52, 84, 106, 120,  
   123, 127  
   based stimuli-responsive 120  
   molecular targeted 84  
 Drug delivery systems (DDS) 83, 90, 107,  
   109, 113, 120, 121, 122, 123, 124, 126,  
   127  
   dependent 83, 90  
   novel 109, 113  
   responsive 107, 121

sensitive 107, 120, 121  
 Drug-loaded 56, 87  
   dendrimer conjugates 56  
   nanoparticulate system 87  
   nano-particulate system 87  
 Drug release 43, 52, 95, 121, 122  
 effective 121  
 influence 95  
 kinetics 52  
   mediated 122  
   triggered 121  
 Drug-resistance, bypassing 15  
 Drug response duration 19  
 Drugs 8, 9, 11, 13, 15, 36, 39, 40, 42, 43, 45,  
   48, 49, 52, 53, 60, 67, 69, 73, 74, 77, 75,  
   85, 87, 88, 93, 107, 109, 111, 112, 113,  
   122, 123, 127  
 allosteric 11  
 anti-angiogenic 113  
 anti-cancerous 123  
 anti-VEGF 73  
 approved 67, 69, 77  
 chemical 67  
 chemotherapeutic 8, 36, 39, 52, 60  
 encapsulated 78, 123  
 entrapped 112  
 hydrophobic 39, 45, 88, 109, 111  
 immunotherapy 67  
 irreversible 93  
 oral 69, 88  
 signaling pathway 15  
 standard chemotherapeutic 11  
 synthetic 73  
 Duocarmycin analogs 120  
 Dynamic lipolysis 92

**E**

Early detection 37, 118  
   of breast cancer 37  
   of Cancer 118  
 Effective 58, 115  
   delivery system 58  
   treatment strategy 115  
 Efficacy 6, 16, 20, 22, 41, 83, 87, 88, 91, 96  
 improved drug 87  
 increased Dasatinib 16  
 oral 83, 88, 91, 96  
 reduced 41  
 significant 20, 22

EGFR 44, 46, 67, 69, 70, 71, 74  
 effects 44  
   exon 69  
   expression 46  
   gene expression 44  
   inhibiting human 71  
   mutant 69  
   mutations in 71, 74  
   targeting 70  
   tyrosine kinase inhibitors 67  
 EGFR inhibitors 2, 71  
   active 71  
   and anti-EGF antibodies 2  
 Endocytosis 45, 58, 53, 56, 107  
   caveolae-mediated 56  
   mediated 45, 58  
   receptor-mediated 44, 45  
 Enzymes 57, 86, 87, 120  
   common metabolizing 87  
   digestive 87  
   major phase-II metabolizing 87  
   metabolic 87  
   overexpressed proteolytic 120  
   restriction 57  
 Epidermal growth factor receptor (EGFR) 2,  
   42, 67, 68, 69, 70, 71, 73, 74, 77  
 Epigenetic changes in lung cancer 67  
 Epithelial cells 18, 37  
   lining 37  
 Epithelial mesenchymal transition 67  
 Estrogen 38  
   production 38  
   receptor 38  
 Estrogens 37, 38  
 Etoposide-phospholipid complex (EPC) 91,  
   93  
 Expression 4, 6, 7, 15, 38, 39, 58, 59, 74, 75,  
   76, 78  
   aberrant 7, 77  
   demonstrated suppressed 58  
   hMLH1 protein 76  
   inhibiting survivin 59

**F**

Factors 4, 6, 16, 71, 72, 73, 75, 113  
 c-mesenchymal-epithelial transition 71  
 growth-regulatory transcription 6  
 hepatic leukemia 4  
 hypoxia-inducible 73



key transcription 75  
platelet-derived growth 16  
vascular endothelial growth 72, 113  
Fibroblasts 106  
  associated 106  
Fluorescent dye 110, 114, 117  
  infrared 110  
Fluorescent substrates 125  
Focal adhesion kinase (FAK) 14, 16  
Folate 39, 42, 110, 111, 115, 126  
  -conjugated PEG-solid fat nanoemulsion 115  
  -conjugated phospholipid 111  
  receptor 42  
Folic acid 43, 47, 48, 53, 110, 111  
  coupling 47  
  polymer-core lipid-shell 53  
Follicular lymphoma (FL) 119  
Food and drug administration (FDA) 67, 69, 70, 71, 72, 73, 74, 77, 116, 118, 119, 120  
Formation, *in-situ* nanoemulsion 90  
FOXO transcription factors 6  
FTO gene expression levels 46  
Fucosylated oligosaccharides 119  
Functional DNAs 114, 121  
  nucleic acids 114  
  polyelectrolyte 121  
Functions 6, 7, 18, 39, 48, 56, 58, 59, 68, 76, 87, 114, 118  
  biological 59  
  cellular normal 68  
  lysosomal 7  
  mitochondrial 56  
  nuclear 6  
  oncogenic 76  
  preserving normal immune 18  
Fusion method 95, 112  
  liposome 112

## G

Gene expressions 56, 59, 75, 106  
  controlled 75  
  regulating 56  
Gene polymorphism 68  
Gene regulators 67  
Genetic 2, 4, 16, 67  
  alterations 2  
  damage 67

  material 4  
  rearrangements 16  
GI membrane 86  
GI-related untoward effect 95  
Glioblastoma 14, 20  
  multiforme 14  
Glycol chitosan (GC) 3, 11, 13, 17, 18, 121  
Graphene nanohybrid (GN) 121  
Graphene oxide 115, 121  
  modified super-paramagnetic 115  
  pH-sensitive nanoscale 121  
Graphene quantum dot (GQDs) 109

## H

Haematological malignancy 22  
HeLa cells 54, 115  
Hematologic 1, 5, 8, 11  
  malignancies 5, 8  
  neoplasms 1, 11  
Hematopoietic stem cell transplantation (HSCT) 15  
Hepatocellular carcinoma 2, 14, 20, 117, 122  
HepG2 cells 114  
  in comparison 114  
HER-2 39, 55, 120  
  targeting 55  
  cell surface protein 120  
  receptors 39  
Herbal 124  
  drugs development 124  
  medicines 124  
Heterogeneity 77  
Heterolipids 83, 88  
High 45, 52, 57  
  antiproliferation in HER2-positive cells 57  
  antitumor activity 52  
  cell internalization and strong anti-cancer effects 45  
Human 42, 45, 92  
  cancer cells 92  
  epidermal growth factor receptor 42  
  serum albumin 45  
Hybrid lipid nanoparticles 53, 54  
Hydrogel 49, 115  
  micelle-based 49  
  pH-sensitive 49  
  salt-based 115  
Hydrogenated 90  
  soybean oil flakes 90

vegetable oils 90  
 Hyperglycemia 11  
 Hyperthermia 122  
 Hypoxia 105, 106, 107, 113  
   cells, raised 113  
 Hypoxic areas of tumor cells 106

**I**

Ideal theranostic systems 107  
 Imatinib mesylate effect 15  
 Immature lymphoid cells 1  
 Immune 37, 59, 72, 74, 116, 119  
   action 119  
   -stimulatory effects 59  
   system 37, 72, 74, 116  
   system attack 72  
 Immunotherapy 67, 72, 84, 116  
   active 72  
   passive 72  
 Implantable gel systems 115  
 Inducing caspase-dependent apoptosis 9  
 Inducing cell death 14  
 Infrared spectroscopy 113  
 Infusion 84, 85, 93, 118  
   intermittent intravenous 85  
 Inhibition 4, 5, 6, 13, 15, 17, 18, 50, 52, 57,  
   58, 71, 76, 88, 91, 115  
   activity 5  
   cytokine signaling 13  
   effective 50, 57, 91  
   higher kinase 71  
   of tumor cell growth 115  
 Inhibitors 2, 3, 8, 9, 10, 13, 14, 15, 16, 19, 20,  
   21, 69, 71, 72, 76, 77, 120  
   allosteric 12  
   antibody-based 72  
   histone deacetylase 21  
   microtubule 120  
   multikinase 2  
   targeted 20  
   targeted cascade 3  
   targeting first-generation 71  
 Intensity 111, 123  
   fluorescence 111  
 Interaction 77, 106  
   ligand receptor 106  
   pembrolizumab target PD-1/PDL-1 77  
 Interleukin 4, 8  
   abrogate 8

receptor 4  
 Intracellular 59, 75  
   restoration 59  
   signal pathways 75  
 Intrinsic anti-cancer activity 47  
 Invasive blood neoplasm 3  
 Ionic complexation 115  
 Iron 109, 114  
   -dependent artesunate 109  
   oxide nanocrystals 114

**K**

Kinase 11, 14, 16, 69  
   activation loop 69  
   focal adhesion 14, 16  
 Kinase domain 67, 69, 71  
   tyrosine 67, 69

**L**

Leukemia hematological disorders 1  
 Leukemias 2, 7, 8, 9, 15, 22, 119, 120  
   acute 7  
   acute myelogenous 120  
   acute myeloid 8  
   chronic lymphocytic 9, 119  
   chronic myeloid 2, 15, 22  
 Leukemic cells 11  
 Leukemogenesis 2  
 Lipids 6, 39, 52, 83, 87, 90, 106, 124  
   biocompatible 83, 90  
   cationic 52  
   dual specificity 6  
   photosensitive 124  
 Liposomal 112, 122, 125  
   encapsulation 125  
   nanocomplex 112  
   system, sensitive 122  
 Liposomes 40, 52, 76, 105, 106, 107, 111,  
   112, 123, 124, 127  
   developed 112  
   entrapped 111, 123  
   modified 112  
   reduction 123  
   targeted 111  
 Low density lipoprotein (LDL) 113  
 Lower critical solution temperature (LCST)  
   122

Low molecular weight chitosan (LMWC) 111  
 Lung cancer 67, 68, 69, 72, 73, 74, 75, 76, 77, 84, 115, 118, 124, 126  
   cell 124  
   diagnosis of 68, 75  
   metastatic 74  
   non-small cell 67, 68, 69, 115  
 Lung carcinoma 67  
 Luteinizing hormone-releasing hormone (LHRH) 44  
 Lymphatic transport, intestinal 87  
 Lymphatic transport pathway, intestinal 88  
 Lymphocytes 4, 18  
 Lymphogenesis 5  
 Lymphoid progenitor cells 3  
 Lymphomas 20, 21, 119, 120  
   non-Hodgkin 119  
   refractory 20  
 Lyophilized preparation 111

## M

Magnetic 111, 114, 118  
   properties 118  
   resonance imaging (MRI) 111, 114  
 Magnetic nanoparticles 55, 109, 113  
   coated 109  
   dendrimer-coated 55  
   surface-engineered 113  
 Malignant 2, 3, 8  
   cells 2  
   hematological disorder 3  
   thymocytes 8  
 Mammary carcinoma tumor 50  
 Management of hepatocellular carcinoma 117, 122  
 MAPK pathways 5, 75  
 Maximum tolerated dose (MTD) 21  
 Maytansinoids 120  
 MDR 52, 54  
   breast cancer 52  
   cancer cells 54  
 Mechanism 7, 14, 15, 67, 69, 70, 72, 73, 126  
   aberrant cellular 14  
   inducing programmed cell death 15  
   inhibitory 67  
   metabolic 7  
 Membrane 67, 111, 123, 124  
   epidermal growth factor receptor 67  
   extrusion 111

  fusion 124  
   organization 123  
 Metalloproteinase 76  
 Metastatic NSCLC 69, 72, 73, 74, 78  
   harbouring 74  
   positive 69  
 Methotrexate 19, 45, 46, 92  
   accumulation 123  
 Micellar systems 47, 48, 49, 54  
 Minimal residual disease (MRD) 3, 21  
 MiRNAs 58, 59, 67, 75, 76, 78  
   cancer-causing 67  
   oncogene 76  
   suppressive 59  
 Modified 52, 111, 118  
   emulsification technique 52  
   liposomal preparation 111  
   SELEX technique 118  
 Monoclonal antibodies 72, 74, 77, 78, 117, 119  
   human 74  
 Mono-nuclear cells 21  
 Monotherapy 113  
 Multidrug 86  
   efflux pumps 86  
   resistance protein 86  
 Multi-drug treatment regimens 84  
 Multifunction delivery systems 107  
 Multiple myeloma 120  
 Mutation harboring cells 15  
 Mutations 4, 5, 15, 16, 37, 67, 69, 70, 71, 74, 77, 112  
   activated JAK 4  
   activating 4, 70  
   genetic 5  
   somatic 4  
   substitution 69  
 Myeloid lineages 3

## N

Nanoemulsion 83, 84, 105, 110, 114, 115, 127  
   ligand-appended 115  
   oil-in-water 114  
 Nanoencapsulated drugs 76  
 Nanoparticles 39, 40, 43, 45, 47, 52, 53, 59, 108, 110, 113, 114, 121, 126  
   conjugated hollow mesoporous CuS 108  
   cyclodextrin 45, 47  
   decorated polyethylenimine-PLGA 59

developed 59, 114  
 encapsulated dextran-coated iron oxide 59  
 hybrid 39, 43, 52, 53  
 inorganic 40  
 lipid core 113  
 liquid crystalline 126  
 magnetic iron oxide 110  
 pH-titratable super paramagnetic Fe<sub>2</sub>O<sub>3</sub> 121  
 silver 40  
 super paramagnetic iron oxide 121  
 Nanoparticle systems 40, 44, 59, 114  
   developed 59  
   exploiting 44  
   polymeric 44  
 Nanoparticle technology 36  
 Nanoscale graphene oxide (NGO) 121  
 Nanosystems 40, 52, 53, 54, 76, 121  
   dendrimer-based 54  
   hybrid 52, 53  
   inorganic 40  
 National institutes of health (NIH) 116  
 Natural killer T-cells 73  
 Nature 39, 75, 97, 88, 96  
   anti-tumorigenic 75  
   biodegradable 39  
   lipophilic 87, 88  
   self-emulsifying 96  
 Necrotic cancer cells 57  
 Neoplastic diseases 1  
 Neo-vascularization, inhibiting 13  
 Network 2, 9, 18  
   inhibition 9, 18  
   stimulation 2  
 Next generation sequencing (NGS) 4  
 Nicotine-derived nitrosamine ketone 68  
 Nilotinib 9, 15, 17  
   -resistant cells 15  
 Niosomes 106, 126  
 NIRF imaging 114  
   of nanoemulsion 114  
 Non-Hodgkin lymphoma (NHL) 119  
 Non-Hodgkin's B-cell Lymphoma 119  
 Non-small-cell lung cancer (NSCLC) 13, 67,  
   68, 69, 71, 72, 73, 74, 76, 77  
 Non-targeted liposomal preparation 111  
 Non-targeted liposomes 111  
 NSCLC 68, 69, 70, 72, 73, 77, 78  
   advanced EGFR-mutant 70  
   lung cancer 68

metastatic EGFR T790M mutation  
   harboring 69  
   nonsquamous 72  
   squamous 73  
   treatment of 70, 73, 77, 78  
 Nucleases enzyme 118  
 Nucleolin, inhibited 118

## O

Oleic acid 90  
 Oligoethylene glycol derivatives 54  
 Oncogenes 6, 76  
 Oncogenesis 2, 6  
   mechanism 2  
 Oncogenic MicroRNA in Lung Cancer 75  
 Ovarian cancer 109, 110, 113, 118  
   metastatic 113  
 Overexpressed cell surface receptors 43  
 Overexpressing cancer cells 52  
 Oxygen consumption 106

## P

Pancreatic adenocarcinoma (PA) 125  
 Panobinostat 21  
 Passive targeting of nanomedicine 41  
 Pathogenesis 113  
 Pathway 7, 22, 40, 58, 67, 116, 124  
   calpain 124  
   cellular 58  
   endocytotic 40  
   glycolytic 7  
   intracellular 22  
   oncogenic 116  
   signalling 58, 67  
 PEGylated 53, 124  
   liposomes, prepared 124  
   octadecyl-quaternized lysine 53  
 Penetration 76, 91, 92, 109  
   enhanced 76  
   improved drug 92  
 Peptides 39, 42, 47, 48, 68, 110, 116, 124  
   homing 48  
   novel taxane-binding 47  
   pro-gastrin-releasing 68  
   self-assembling 116  
 Perifosine 11, 12  
   alkylphospholipid 11

Permeability 41, 54, 86, 106, 125  
 enhanced 41, 106, 125  
 high membrane 54  
 limited 86  
 Permeation 43, 51, 96  
 enhanced 43  
 improved 51  
 Pharmacokinetic results 50  
 Phosphoinositide 5, 6  
 -dependent protein kinase-1 6  
 Phosphorylation 6, 18, 21, 69, 70, 71  
 mediated 6  
 tyrosine 71  
*Piper nigrum* 124  
 Platelet derived growth factor receptor beta  
 (PDGFRB) 4, 16  
 PLGA-PEG 43, 44, 45, 46  
 bifunctional nanoparticles 45  
 copolymer nanoparticles 46  
 nanoparticles 44, 46  
 Polymer-lipid hybrid system 53, 54  
 Polymers 39, 40, 43, 48, 49, 52, 95, 106, 107,  
 113, 114, 121, 122, 125  
 conjugated 49  
 hydrophilic 107  
 synthesized mPEG-PLGA 48  
 synthetic 106  
 Polymorphisms 5  
 Polyoxyethylene 95  
 Polyunsaturated fatty acids, exploiting 92  
 Post-translation repression 59  
 Precursor 4, 14  
 childhood B-cell 4  
 -B-cell receptor 14  
 Pre-systemic metabolism 86  
 Proapoptotic role 8  
 Process 60, 88  
 material excretion 60  
 self-emulsification 88  
 Progesterone receptor 38  
 Prognosis 3, 75  
 Programmed cell death 73  
 ligand 73  
 protein 73  
 Protein kinase 6, 68  
 Proteins 6, 7, 13, 14, 15, 16, 18, 21, 72, 83,  
 86, 111, 116  
 adaptor 7  
 anti-apoptotic MDM2 15  
 cleaved caspase-3 apoptotic 16

cytoplasmic transport 86  
 immunophilin FK506 binding 13  
 multidrug efflux 83, 86  
 proapoptotic 18  
 proapoptotic BIM 14  
 ribosomal 21  
 PTEN 6, 8  
 and loss of activity 6  
 post-translational inactivation 8  
 PTX nanoemulsion (PNs) 115  
 Pulmonary hypertension 73  
 Puma's expression modulation 21

## R

Radioisotope, immune 119  
 RAS protein 75  
 Reactive oxygen species (ROS) 109, 125  
 Receptor-mediated endocytosis process 114  
 Receptor tyrosine kinases 2, 6  
 Recognition 106, 111, 116  
 antibody-antigen 106  
 Relapsed multiple myeloma 21  
 Resistance 11, 68, 123  
 mutations 68  
 oxidative stress 123  
 steroid 11  
 Reticuloendothelial system 42  
 Rheumatoid arthritis 126  
 RNA 58, 59, 76, 127  
 gene 1-small interference 59  
 induced silencing complex (RISC) 76  
 interference (RNAi) 58  
 therapeutics 127  
 Rolling circle amplification (RCA) 114  
 ROS 77, 126  
 production 126  
 proteins 77

## S

Selective estrogen receptor modulator 38  
 Self 83, 87, 88, 47, 90, 91, 94  
 -assembled chitosan nanoparticles 47  
 -emulsification performance 94  
 -emulsifying drug delivery system 90, 91  
 -nanoemulsifying drug delivery system 83,  
 87, 88  
 Serum urea 92

- Signaling 3, 15
    - pathway downstream 15
    - tyrosine kinases 3
  - Signal 1, 93, 112
    - transduction 1
    - chain antibody fragment 112
    - dose studies 93
    - walled carbon nanotubes 127
  - SiRNA 58, 77
    - developed A2AR-specific 58
    - nanoencapsulated 77
  - SiRNA molecules 58
  - Small 1, 3, 12, 15, 22, 67, 68, 77, 124
    - cell lung cancers (SCLC) 67, 68, 77, 124
    - molecule inhibitors (SMIs) 1, 3, 12, 15, 22
    - molecule kinase inhibitors 68
  - Solidification 94, 95
    - process 95
    - techniques 94, 95
  - Solid tumors 1, 14, 20, 112, 120
  - Src family kinases 7
  - Stimuli 6, 105, 106, 107, 114, 115, 120, 121, 122, 123, 127
    - endogenous 127
    - external magnetic 123
    - extracellular 6
    - magnetic 123
    - sensitive drug delivery systems 120
    - triggered drug delivery systems 127
  - Suppress feedback activation 15
  - Surfactants 83, 87, 88, 90, 93, 95
    - toxic 93
  - Synergistic effect 49
  - Synergism 10, 14, 16, 17
  - Synergistic action 112
  - Synthetic macromolecular structures 54
- T**
- Target 48, 58
    - breast cancer 48
    - cancer cells 58
  - Targeted therapies 1, 2, 68
    - developing new 2
    - molecular 68
  - Targeting breast cancer 115
  - Taxane-binding peptide (TBP) 47
  - T-cell progenitors 5, 18
    - immature 5
  - T-cells 3, 72, 73, 120
    - lymphoblastic 3
  - Temperature sensitive drug delivery systems 122
  - Theranostic 107, 114, 118
    - system 107, 114
    - monoclonal antibodies 118
  - Therapies 12, 37, 38, 44, 48, 49, 58, 68, 74, 78, 84, 85, 105, 109, 114, 116, 127
    - cytotoxic 84
    - directed 114
    - effective 44
    - epigenetic 74, 78
    - first oncolytic virus 116
    - gene transfer 116
    - hormonal 38, 84
    - immunosuppressant 105
    - implementing gene 58
    - photodynamic 109
    - photothermal 49, 109
  - Transferases 87
  - Transferrin receptor 42
  - Transformation 3,4, 7
    - impaired leukemic 7
    - leukemia cells 4
  - Translocations 4
    - reciprocal 4
    - variant 4
  - Trastuzumab 39, 55, 57, 72, 120
    - emtansine 120
    - synthesized 55
  - Treatment 60, 77, 84, 108, 115, 125
    - combinatorial 108
    - conventional breast cancer 60
    - effective 125
    - effective cancer 84
    - localized cancer 115
    - single drug 77
  - Triple negative breast cancer (TNBC) 39, 43
  - Tuberous sclerosis 7
  - Tumor cells 40, 42, 52, 72, 73, 74, 106, 107, 109, 112, 114, 116, 118, 124, 125
    - circulating 118
    - proliferation 52, 109
    - targeted malignant 124
  - Tumor growth 13, 38, 49, 50, 56, 59, 70, 73, 74, 105, 109, 115, 122
    - inhibition effect 50
    - inhibiting 49
    - reduced 50
    - support 70

*Subject Index*

suppressed 115  
Tumors 37, 38, 39, 40, 41, 42, 44, 47, 48, 52,  
53, 54, 57, 68, 77, 106, 109, 117, 122,  
124  
breast 54, 57  
gastrointestinal 117  
induced 44  
initial 37  
necrotic 68  
overexpressed 52  
Tumor suppressor gene 2, 6, 76, 74, 75, 112  
inhibiting 76  
phosphatase 2  
upstream 6  
Tumor suppressor(s) 75, 76  
MicroRNAs in Lung Cancer 75  
Tumor vasculature 55, 106  
restricted 106  
Tumor vasculature cells 106  
Turbid emulsions 94  
Tyrosine kinase 1, 3, 9, 15, 16, 67, 68, 69, 70  
activity 68, 69  
inhibitors (TKIs) 1, 3, 9, 15, 16, 67, 70  
TZ-conjugation of dendrimers 55

**U**

Ubiquitin ligase 6  
Upper critical solution temperature (UCST)  
122  
Uptake 47, 107, 113  
intracellular 47  
macrophagic 113  
reticulo-endothelial system 107  
Ursolic acid (UA) 125

**V**

Vascular endothelial growth factor (VEGF)  
72, 73, 75, 113  
receptor (VEGFR) 73  
VEGF 2, 55, 111  
-antisense oligodeoxynucleotides 55  
gene expression 111  
/RAF/RAS pathway 2  
Venous catheter 85  
Vessels, lymphatic 52  
Viability 9, 18, 96  
cellular 9

*Frontiers in Anti-Cancer Drug Discovery, Vol. 11 151*


preserving lymphocyte 18  
Vincristine 9, 11, 16, 20, 43, 45, 86  
sulfate 43, 45  
Viruses 116, 117  
non-oncolytic 116

**W**

Weighted magnetic resonance contrast agent  
121  
Western blot 116, 126  
study 126  
technique 116

**X**

Xenobiotics 87, 88



## PROF. DR. ATTA-UR-RAHMAN, FRS

---

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.



## PROF. DR. M. IQBAL CHOUDHARY

---

Dr. M. Iqbal Choudhary is a Professor of Organic/Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research) and Coordinator General of COMSTECH (OIC Ministerial Committee). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 1000 research papers and chapters in top international science journals of the West as well as 27 US patents (H-index: 68 & Citations: 27,500). He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University of Rhode Island (Rhode Island), and other top Universities.